{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:40:07Z","timestamp":1791214807748,"version":"4.1.0"},"reference-count":25,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,11,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Adult T-cell leukemia (ATL) is a highly chemoresistant and usually fatal T-cell malignancy due to the human T-cell lymphotropic virus-1 (HTLV-1). After chemotherapy failure, antiretrovirals and interferon-\u03b1 (IFN-\u03b1) produce brief responses followed by progression and death. More effective agents and new approaches to detect and treat minimal residual disease are needed. ATL cells express CD52, the target of the antibody alemtuzumab, which is active in a preclinical model of ATL and is cytotoxic for p53-deficient cells. A patient with refractory chronic ATL in transformation achieved longer than a 1-year complete hematologic response following 12 weeks of outpatient subcutaneous alemtuzumab. Persistent suppression of HTLV-1 viral load, even at recovery of T cells, after alemtuzumab and efficient in vitro complement-mediated cytotoxicity of primary ATL cells with mutated TP53 were observed. The unprecedented response and the profound suppression of HTLV-1 viral load observed in this patient suggest that further clinical investigation of alemtuzumab in ATL is warranted.<\/jats:p>","DOI":"10.1182\/blood-2005-01-0335","type":"journal-article","created":{"date-parts":[[2005,8,3]],"date-time":"2005-08-03T02:33:11Z","timestamp":1123036391000},"page":"3380-3382","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":45,"title":["Durable hematologic complete response and suppression of HTLV-1 viral load following alemtuzumab in zidovudine\/IFN-\u03b1\u2013refractory adult T-cell leukemia"],"prefix":"10.1182","volume":"106","author":[{"given":"Andrew","family":"Mone","sequence":"first","affiliation":[{"name":"From the Division of Hematology-Oncology, Department of Internal Medicine; The Comprehensive Cancer Center; and the Division of Dermatopathology, Department of Pathology, The Ohio State University, Columbus."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Puhalla","sequence":"additional","affiliation":[{"name":"From the Division of Hematology-Oncology, Department of Internal Medicine; The Comprehensive Cancer Center; and the Division of Dermatopathology, Department of Pathology, The Ohio State University, Columbus."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Whitman","sequence":"additional","affiliation":[{"name":"From the Division of Hematology-Oncology, Department of Internal Medicine; The Comprehensive Cancer Center; and the Division of Dermatopathology, Department of Pathology, The Ohio State University, Columbus."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Baiocchi","sequence":"additional","affiliation":[{"name":"From the Division of Hematology-Oncology, Department of Internal Medicine; The Comprehensive Cancer Center; and the Division of Dermatopathology, Department of Pathology, The Ohio State University, Columbus."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Cruz","sequence":"additional","affiliation":[{"name":"From the Division of Hematology-Oncology, Department of Internal Medicine; The Comprehensive Cancer Center; and the Division of Dermatopathology, Department of Pathology, The Ohio State University, Columbus."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Vukosavljevic","sequence":"additional","affiliation":[{"name":"From the Division of Hematology-Oncology, Department of Internal Medicine; The Comprehensive Cancer Center; and the Division of Dermatopathology, Department of Pathology, The Ohio State University, Columbus."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Banks","sequence":"additional","affiliation":[{"name":"From the Division of Hematology-Oncology, Department of Internal Medicine; The Comprehensive Cancer Center; and the Division of Dermatopathology, Department of Pathology, The Ohio State University, Columbus."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles F.","family":"Eisenbeis","sequence":"additional","affiliation":[{"name":"From the Division of Hematology-Oncology, Department of Internal Medicine; The Comprehensive Cancer Center; and the Division of Dermatopathology, Department of Pathology, The Ohio State University, Columbus."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Byrd","sequence":"additional","affiliation":[{"name":"From the Division of Hematology-Oncology, Department of Internal Medicine; The Comprehensive Cancer Center; and the Division of Dermatopathology, Department of Pathology, The Ohio State University, Columbus."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Caligiuri","sequence":"additional","affiliation":[{"name":"From the Division of Hematology-Oncology, Department of Internal Medicine; The Comprehensive Cancer Center; and the Division of Dermatopathology, Department of Pathology, The Ohio State University, Columbus."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Porcu","sequence":"additional","affiliation":[{"name":"From the Division of Hematology-Oncology, Department of Internal Medicine; The Comprehensive Cancer Center; and the Division of Dermatopathology, Department of Pathology, The Ohio State University, Columbus."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021217543146900_REF1","unstructured":"Maloney EM, Blattner WA. HTLV-1 worldwide patterns and disease associations. In: Sugamura K, Uchiyama T, Matsuoka M, and Kannagi M, eds. Gann Monographs on Cancer Research. Vol 50. Japan Science Societies Press; 2003: 339-361."},{"key":"2020021217543146900_REF2","doi-asserted-by":"crossref","unstructured":"Ratner L. Adult T cell leukemia lymphoma. Front Biosci. 2004;9: 2852-2859.","DOI":"10.2741\/1442"},{"key":"2020021217543146900_REF3","doi-asserted-by":"crossref","unstructured":"Yamada Y, Tomonaga M. The current status of therapy for adult T-cell leukaemia-lymphoma in Japan. Leuk Lymphoma. 2003;44: 611-618.","DOI":"10.1080\/1042819021000055039"},{"key":"2020021217543146900_REF4","doi-asserted-by":"crossref","unstructured":"Hatta Y, Koeffler HP. Role of tumor suppressor genes in the development of adult T cell leukemia\/lymphoma (ATLL). Leukemia. 2002;16: 1069-1085.","DOI":"10.1038\/sj.leu.2402458"},{"key":"2020021217543146900_REF5","doi-asserted-by":"crossref","unstructured":"Sun SC, Ballard DW. Persistent activation of NF-kappaB by the tax transforming protein of HTLV-1: hijacking cellular IkappaB kinases. Oncogene. 1999;18: 6948-6958.","DOI":"10.1038\/sj.onc.1203220"},{"key":"2020021217543146900_REF6","doi-asserted-by":"crossref","unstructured":"Kamihira S, Dateki N, Sugahara K, et al. Significance of HTLV-1 proviral load quantification by real-time PCR as a surrogate marker for HTLV-1-infected cell count. Clin Lab Haematol. 2003;25: 111-117.","DOI":"10.1046\/j.1365-2257.2003.00503.x"},{"key":"2020021217543146900_REF7","doi-asserted-by":"crossref","unstructured":"Hale G. The CD52 antigen and development of the CAMPATH antibodies. Cytotherapy. 2001;3: 137-143.","DOI":"10.1080\/146532401753174098"},{"key":"2020021217543146900_REF8","unstructured":"Zhang Z, Zhang M, Goldman CK, Ravetch JV, Waldmann TA. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H. Cancer Res. 2003;63: 6453-6457."},{"key":"2020021217543146900_REF9","doi-asserted-by":"crossref","unstructured":"Miley WJ, Suryanarayana K, Manns A, et al. Real-time polymerase chain reaction assay for cell-associated HTLV type I DNA viral load. AIDS Res Hum Retroviruses. 2000;16: 665-675.","DOI":"10.1089\/088922200308891"},{"key":"2020021217543146900_REF10","doi-asserted-by":"crossref","unstructured":"Hale G, Clark M, Waldmann H. Therapeutic potential of rat monoclonal antibodies: isotype specificity of antibody-dependent cell-mediated cytotoxicity with human lymphocytes. J Immunol. 1985;134: 3056-3061.","DOI":"10.4049\/jimmunol.134.5.3056"},{"key":"2020021217543146900_REF11","doi-asserted-by":"crossref","unstructured":"Mone AP, Huang P, Pelicano H, et al. Hu1D10 induces apoptosis concurrent with activation of the AKT survival pathway in human chronic lymphocytic leukemia cells. Blood. 2004;103: 1846-1854.","DOI":"10.1182\/blood-2003-08-2836"},{"key":"2020021217543146900_REF12","doi-asserted-by":"crossref","unstructured":"Lozanski G, Heerema NA, Flinn IW, et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood. 2004;103: 3278-3281.","DOI":"10.1182\/blood-2003-10-3729"},{"key":"2020021217543146900_","doi-asserted-by":"crossref","unstructured":"Dearden CE, Matutes E, Cazin B, et al. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood. 2001;98: 1721-1726.","DOI":"10.1182\/blood.V98.6.1721"},{"key":"2020021217543146900_","doi-asserted-by":"crossref","unstructured":"Lundin J, Hagberg H, Repp R, et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides\/Sezary syndrome. Blood. 2003;101: 4267-4272.","DOI":"10.1182\/blood-2002-09-2802"},{"key":"2020021217543146900_","doi-asserted-by":"crossref","unstructured":"Dearden C. Alemtuzumab in peripheral T-cell malignancies. Cancer Biother Radiopharm. 2004;19: 391-398.","DOI":"10.1089\/1084978041979661"},{"key":"2020021217543146900_REF16","doi-asserted-by":"crossref","unstructured":"Stilgenbauer S, Dohner H. Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N Engl J Med. 2002;347: 452-453.","DOI":"10.1056\/NEJM200208083470619"},{"key":"2020021217543146900_REF17","doi-asserted-by":"crossref","unstructured":"Abe Y, Yashiki S, Choi I, et al. Eradication of virus-infected T-cells in a case of adult T-cell leukemia\/lymphoma by nonmyeloablative peripheral blood stem cell transplantation with conditioning consisting of low-dose total body irradiation and pentostatin. Int J Hematol. 2002;76: 91-93.","DOI":"10.1007\/BF02982725"},{"key":"2020021217543146900_","unstructured":"Tajima K, Amakawa R, Uehira K, et al. Adult T-cell leukemia successfully treated with allogeneic bone marrow transplantation. Int J Hematol. 2000;71: 290-293."},{"key":"2020021217543146900_REF19","doi-asserted-by":"crossref","unstructured":"Hishizawa M, Imada K, Ishikawa T, Uchiyama T. Kinetics of proviral DNA load, soluble interleukin-2 receptor level and tax expression in patients with adult T-cell leukemia receiving allogeneic stem cell transplantation. Leukemia. 2004;18: 167-169.","DOI":"10.1038\/sj.leu.2403204"},{"key":"2020021217543146900_REF20","doi-asserted-by":"crossref","unstructured":"Dearden CE, Matutes E, Catovsky D. Alemtuzumab in T-cell malignancies. Med Oncol. 2002; 19(suppl): S27-S32.","DOI":"10.1385\/MO:19:2S:S27"},{"key":"2020021217543146900_REF21","unstructured":"Morris JC, O'Mahony D, Lee CC, et al. A phase II study of the efficacy and toxicity of Campath-1H (anti-CD52) for the therapy of adult T-cell leukemia (ATL): early results. AIDS Res Hum Retroviruses. 2005;21: 446. Abstract 022."},{"key":"2020021217543146900_REF22","doi-asserted-by":"crossref","unstructured":"Lin TS, Flinn IW, Modali R, et al. FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia. Blood. 2005;105: 289-291.","DOI":"10.1182\/blood-2004-02-0651"},{"key":"2020021217543146900_REF23","doi-asserted-by":"crossref","unstructured":"Harashima N, Kurihara K, Utsunomiya A, et al. Graft-versus-Tax response in adult T-cell leukemia patients after hematopoietic stem cell transplantation. Cancer Res. 2004;64: 391-399.","DOI":"10.1158\/0008-5472.CAN-03-1452"},{"key":"2020021217543146900_REF24","doi-asserted-by":"crossref","unstructured":"Mortreux F, Gabet AS, Wattel E. Molecular and cellular aspects of HTLV-1 associated leukemogenesis in vivo. Leukemia. 2003;17: 26-38.","DOI":"10.1038\/sj.leu.2402777"},{"key":"2020021217543146900_REF25","doi-asserted-by":"crossref","unstructured":"Lundin J, Kimby E, Bjorkholm M, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood. 2002;100: 768-773.","DOI":"10.1182\/blood-2002-01-0159"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/106\/10\/3380\/1636401\/zh802205003380.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/106\/10\/3380\/1636401\/zh802205003380.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T23:43:33Z","timestamp":1683157413000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/106\/10\/3380\/20906\/Durable-hematologic-complete-response-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11,15]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2005,11,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2005-01-0335","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,11,15]]}}}